CA3246018A1 - PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLDIAZOLE DERIVATIVES AND METHODS OF USE - Google Patents
PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLDIAZOLE DERIVATIVES AND METHODS OF USEInfo
- Publication number
- CA3246018A1 CA3246018A1 CA3246018A CA3246018A CA3246018A1 CA 3246018 A1 CA3246018 A1 CA 3246018A1 CA 3246018 A CA3246018 A CA 3246018A CA 3246018 A CA3246018 A CA 3246018A CA 3246018 A1 CA3246018 A1 CA 3246018A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- anlel38b
- fatty acid
- excipient
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159408 | 2022-03-01 | ||
| EP22159408.8 | 2022-03-01 | ||
| PCT/EP2023/055160 WO2023166045A1 (en) | 2022-03-01 | 2023-03-01 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246018A1 true CA3246018A1 (en) | 2023-09-07 |
Family
ID=80623476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246018A Pending CA3246018A1 (en) | 2022-03-01 | 2023-03-01 | PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLDIAZOLE DERIVATIVES AND METHODS OF USE |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250161273A1 (https=) |
| EP (1) | EP4486340A1 (https=) |
| JP (1) | JP2025508912A (https=) |
| KR (1) | KR20240155237A (https=) |
| CN (1) | CN118715010A (https=) |
| AU (1) | AU2023227368A1 (https=) |
| CA (1) | CA3246018A1 (https=) |
| CL (1) | CL2024002379A1 (https=) |
| IL (1) | IL314952A (https=) |
| MX (1) | MX2024009773A (https=) |
| PE (1) | PE20250781A1 (https=) |
| WO (1) | WO2023166045A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025068949A1 (en) | 2023-09-26 | 2025-04-03 | Teva Pharmaceutical Industries Ltd. | Emrusolmin for use in treating multiple system atrophy |
| KR20250090047A (ko) * | 2023-12-12 | 2025-06-19 | 가천대학교 산학협력단 | 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2687513B1 (en) * | 2008-06-09 | 2020-12-02 | Ludwig-Maximilians-Universität München | Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| KR102671166B1 (ko) * | 2015-12-14 | 2024-05-31 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 3,5-디페닐-디아졸 화합물의 수용성 유도체 |
-
2023
- 2023-03-01 US US18/840,374 patent/US20250161273A1/en active Pending
- 2023-03-01 PE PE2024001775A patent/PE20250781A1/es unknown
- 2023-03-01 WO PCT/EP2023/055160 patent/WO2023166045A1/en not_active Ceased
- 2023-03-01 KR KR1020247029979A patent/KR20240155237A/ko active Pending
- 2023-03-01 JP JP2024550866A patent/JP2025508912A/ja active Pending
- 2023-03-01 CN CN202380024479.XA patent/CN118715010A/zh active Pending
- 2023-03-01 EP EP23707119.6A patent/EP4486340A1/en active Pending
- 2023-03-01 CA CA3246018A patent/CA3246018A1/en active Pending
- 2023-03-01 MX MX2024009773A patent/MX2024009773A/es unknown
- 2023-03-01 AU AU2023227368A patent/AU2023227368A1/en active Pending
- 2023-03-01 IL IL314952A patent/IL314952A/en unknown
-
2024
- 2024-08-08 CL CL2024002379A patent/CL2024002379A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250161273A1 (en) | 2025-05-22 |
| CL2024002379A1 (es) | 2025-01-24 |
| WO2023166045A1 (en) | 2023-09-07 |
| KR20240155237A (ko) | 2024-10-28 |
| EP4486340A1 (en) | 2025-01-08 |
| MX2024009773A (es) | 2024-08-19 |
| IL314952A (en) | 2024-10-01 |
| AU2023227368A1 (en) | 2024-07-18 |
| JP2025508912A (ja) | 2025-04-10 |
| CN118715010A (zh) | 2024-09-27 |
| PE20250781A1 (es) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220152058A1 (en) | Methods and compositions for treating various disorders | |
| JP2017081930A (ja) | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 | |
| KR20140101333A (ko) | 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료 | |
| US20250161273A1 (en) | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use | |
| US20100099723A1 (en) | Bioavailable compositions of metaxalone and processes for producing the same | |
| ES2983643T3 (es) | Terapia oral con tridecanoato de testosterona | |
| JP7391403B2 (ja) | ヒドロキシピリドネートアクチニド／ランタニド体外除去剤の製剤 | |
| US20160310481A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders | |
| JP7120691B2 (ja) | 非アルコール性脂肪肝炎の予防または治療用の薬学組成物 | |
| WO2020072814A1 (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| JP5678088B2 (ja) | ４−メチルピラゾール製剤 | |
| US20150174118A1 (en) | Use of laquinimod to delay huntington's disease progression | |
| KR20160146664A (ko) | 심장혈관 질환의 치료 또는 예방에서 사용하기 위한 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 저해인자 및 상기 저해인자를 포함하는 약학적 조성물 | |
| EA052714B1 (ru) | Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения | |
| US20240165093A1 (en) | Methods for treating familial chylomicronemia syndrome | |
| HK40115748A (zh) | 包含二苯基二唑衍生物的药物组合物及其使用方法 | |
| KR20240036651A (ko) | 산화성 망막 질환의 진행을 억제하는 방법 | |
| CN116323604A (zh) | 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂 | |
| WO2025068949A1 (en) | Emrusolmin for use in treating multiple system atrophy | |
| WO2024210195A1 (ja) | 炎症性腸疾患の治療用医薬組成物 | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| CN118742299A (zh) | 监测患者对视网膜氧化性疾病治疗反应的方法 | |
| WO2026088136A1 (en) | Methods of treating a neurodegenerative disease | |
| CN121466010A (zh) | 阿托西班组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240703 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241004 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241004 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241004 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250219 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250822 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250825 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260126 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260218 |